Stocks and Investing
Stocks and Investing
Thu, November 3, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, November 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gena Wang Upgraded (ARCT) to Hold and Increased Target to $25 on, Nov 2nd, 2022
Gena Wang of Barclays, Upgraded "Arcturus Therapeutics Holdings Inc." (ARCT) to Hold and Increased Target from $16 to $25 on, Nov 2nd, 2022.
Gena has made no other calls on ARCT in the last 4 months.
There are 3 other peers that have a rating on ARCT. Out of the 3 peers that are also analyzing ARCT, 0 agree with Gena's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Gena
- John Abbott of "Wells Fargo" Maintained at Buy with Decreased Target to $98 on, Wednesday, August 10th, 2022
- Steven Seedhouse of "Raymond James" Downgraded from Hold to Sell on, Wednesday, August 10th, 2022
- Pete Stravropoulos of "Cantor Fitzgerald" Initiated at Buy and Held Target at $39 on, Tuesday, July 19th, 2022
Contributing Sources